Pay in 4 interest-free payments of $5.00 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
The biological activity of the peptide could be lost
Metsera will use its IPO proceeds to fund the Phase III development of its injectable, ultra-long-acting GLP-1 therapy MET-097i, which last week achieved 11.3% weight loss in a Phase IIa study
Both hormones are rapidly released after ingestion, apparently under neural control, and stimulate insulin production in pancreatic cells in a glucose-dependent manner
Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
US$ 21.55
US$ 27.31
US$ 23.59
US$ 21.50
